Legato Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Legato Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,705	Closed	-$223K	–	543
2022 Q4	$223K	Buy	+6,705	New	+$216K	0.04%	438
2017 Q2	–	Sell	-2,111	Closed	-$29K	–	194
2017 Q1	$29K	Hold	2,111	–	–	0.03%	99
2016 Q4	$37.4K	Buy	+2,111	New	+$37.1K	0.68%	74

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Legato Capital Management's VIVO Position: Q1 2023 in Review

Legato Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 6,705 shares — an estimated $223K sold.

Legato Capital Management first reported a position in VIVO in Q4 2016 and held it in 3 quarters. The position peaked at $223K in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Legato Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Legato Capital Management sold 6,705 Meridian Bioscience Inc shares in Q1 2023, an estimated $223K.
Legato Capital Management first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 3 quarters.
Legato Capital Management's Meridian Bioscience Inc position peaked at $223K in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Legato Capital Management's 13F filing for Q1 2023, filed 25 May 2023.